Johnson & Johnson shares surged approximately 13.5% over the past 30 days, climbing from $232.16 on June 8 to $263.40 on July 8, 2026, hitting a new 52-week high of $269.43 during the period. A Guggenheim upgrade to $270 with a "Top Pick" designation in large-cap biopharma triggered sharp buying momentum on June 26, accelerating the rally into quarter-end.

The Tema Oncology ETF surged approximately 13.6% over the past 30 days, driven by a wave of landmark oncology drug approvals and positive clinical data. Over the last quarter, CANC delivered a total return of roughly 12.2%, reflecting sustained momentum across the biotechnology and precision oncology sectors.

METV is a passively managed thematic ETF tracking the Ball Metaverse Index, holding 41 globally-listed equities spanning hardware, compute, networking, virtual platforms, payments, and content categories tied to the metaverse theme. The fund's portfolio is heavily concentrated in Technology Services (40%) and Electronic Technology (37%), with top holdings including AAPL , RBLX , NVDA , and GOOGL , alongside indirect cryptocurrency exposure through Canadian-listed crypto staking ETFs.

SVXY gained approximately 11% over the last 30 days, driven by a sustained decline in expected equity market volatility. The fund provides -0.5x daily inverse exposure to the S&P 500 VIX Short-Term Futures Index, benefiting when VIX futures prices fall.

URTY surged approximately 13.7% over the last 30 days, amplifying a powerful small-cap equity rally through its 3x daily leveraged exposure to the Russell 2000 Index. The Russell 2000 completed its strongest first half since 1991, gaining 22% year-to-date, as the artificial intelligence investment cycle broadened beyond mega-cap technology companies into smaller suppliers and semiconductor equipment firms.

DFEN surged approximately 17% over the past 30 days, driven by a powerful rally in aerospace and defense stocks. The quarterly performance was a more modest gain of roughly 3%, reflecting earlier weakness followed by a sharp recovery.

DPST surged approximately 14.5% over the past 30 days, driven by a powerful rally in U.S. regional bank stocks amplified by the fund's 3x daily leveraged structure. The quarterly performance is even stronger at roughly 23.9%, reflecting sustained bullish momentum across the regional banking sector since mid-April.

XPH surged approximately 16% over the last 30 days, driven by broad-based strength across small- and mid-cap pharmaceutical holdings. The ETF's modified equal-weighted structure amplified gains from high-growth names such as Corcept Therapeutics , Liquidia Corp , and Definium Therapeutics .

SCO surged approximately 33% over the past 30 days as crude oil prices collapsed, driven by the reopening of the Strait of Hormuz and a historic supply glut. The fund's -2x leveraged inverse structure amplifies daily moves in the opposite direction of the Bloomberg Commodity Balanced WTI Crude Oil Index, magnifying gains when oil prices fall.

UDOW surged approximately 15% over the last 30 days, driven by a powerful rally in the Dow Jones Industrial Average amplified by the fund's 3x daily leveraged structure. Over the last quarter, the ETF has gained roughly 28%, reflecting sustained upward momentum across blue-chip industrial and financial holdings.

Global economic growth expectations and interest rate trajectories in developed economies outside the U.S. represent key macro drivers for international quality equities. Sector outlooks in technology, healthcare, and industrials could shape performance given the ETF’s emphasis on high-quality companies with strong return-on-equity profiles.

The U.S. Global Jets ETF (JETS) surged approximately 17% over the past 30 days, reflecting a powerful rally across global airline and travel-related equities. Over the last quarter, the ETF extended a sharp recovery from first-quarter lows, driven by robust air travel demand, rising airfares, and declining jet fuel costs.

TNA surged approximately 13% over the past 30 days, amplifying a powerful rally in U.S. small-cap equities. The Russell 2000 Index posted its strongest first-half performance since 1991, driven by the AI infrastructure buildout broadening beyond mega-cap technology names.

SLDB shares fell -10.77% during regular market trading on July 10, dropping to $9.94 from a previous close of $11.14, as a broad small-cap biotech sell-off took hold. The primary catalyst was a macro-driven sector flush, with re-emerging inflation anxieties and rising bond yields triggering a risk-off rotation away from high-beta, pre-revenue biotech names.

ARKW is an actively managed ETF targeting next-generation internet companies across cloud computing, artificial intelligence, blockchain, digital media, and e-commerce, with approximately 46 holdings and assets under management (AUM) of roughly $1.7 billion. The fund carries a concentrated, high-conviction portfolio with over 50% of assets in its top 10 holdings, led by TSLA , AMD , and HOOD .

GENB shares plunged -9.92% during regular trading on Thursday, falling from a prior close of $15.72 to $14.16, with no specific company news catalyst emerging in the past 24 hours. The sell-off appears to be a sharp profit-taking unwind after a recent rally fueled by the stock's inclusion in the Russell 2000 Index and steady accumulation by ARK Invest.

ULCC shares plunged -10.91% during regular trading hours on Friday, falling from a prior close of $7.70 to $6.86 as a broad travel-sector sell-off intensified. The primary catalyst was a geopolitical shock: President Trump declared the Iran ceasefire "over" and ordered renewed military strikes, sending crude oil prices surging more than +7%.

PRME shares fell -12.29% during regular trading to $3.71, retreating sharply from the prior close of $4.23 as profit-taking set in after a blistering rally. The stock had surged over +50% in the preceding three weeks following a July 6 arbitration victory against Beam Therapeutics that removed legal uncertainty around its lead PM647 gene-editing program.

ARKG surged approximately 25% over the last 30 days, driven by a powerful rally across genomics, precision medicine, and AI-enabled drug discovery holdings. The fund has gained roughly 54% over the last quarter, reflecting a sustained rotation into innovative healthcare and biotechnology equities.

FAS surged approximately 20% over the last 30 days, driven by a powerful rally in U.S. financial stocks amplified by the fund's 3x daily leverage. The quarterly trend is also strongly positive, with FAS gaining roughly 27% over the past three months.